LDS/Medical Tests/Thyroid Cancer Gene Panel from FNA (Afirma®, ThyGenX/ThyraMIR, ThyroSeq v2, RosettaGX Reveal)

Thyroid Cancer Gene Panel from FNA (Afirma®, ThyGenX/ThyraMIR, ThyroSeq v2, RosettaGX Reveal)

A thyroid nodule is usually asymptomatic and is often discovered randomly during a physical exam or during unrelated imaging studies. While thyroid nodules are usually benign (90%), about 10% are malignant. Therefore, although thyroid nodules may or may not be associated with thyroid dysfunction or local mass effects, they should be evaluated due to the risk of malignancy.

The most common procedure for the evaluation of a thyroid nodule is fine needle aspiration (FNA) and cytologic assessment. The main limitation of this procedure is that approximately 20–25% of FNA samples will be reported as indeterminate and further studies are required for diagnosis and management. Studies have shown that in patients undergoing subsequent surgical removal of the nodule, 70-80% are determined to be benign conditions. Therefore, efforts have been made to evaluate that ability of genetic testing to decrease or eliminate such indeterminate diagnosis for FNA.

Several genetic tests have been developed to identify genetic alterations in biopsy tissue associated with thyroid cancer that will help differentiation benign from malignant lesions. Four very similar genomic tests are available today including: Afirma, ThyroSeq v2, ThyGenX/ThyraMIR and RosettaGX Reveal. Although, these assays might use different detection method, all detect the most common gene mutations related to thyroid cancer and treatment. Therefore, their clinical claims and intended use are the same: pre-operative assessment of thyroid nodules with indeterminate FNA cytology. Simply, these assays are designed to identify benign thyroid nodules among those deemed indeterminate by cytopathology, so that patients can potentially avoid surgery and be monitored with CT imaging instead.

The Afirma Thyroid FNA Analysis

The Afirma Thyroid FNA Analysis also known as The Afirma Gene Expression Classifier is a test based on microarray technology used to analyze the mRNA expression of 167 different genes. These 167 genes are in 2 sets, one with 25 genes representing fewer common entities seen in the thyroid and another with 142 genes covering the most common types of thyroid cancer. The selected gene profiles are based on gene expression profiles identified from FNAs of surgically proven benign and malignant thyroid nodules. Two dedicated FNA biopsies are collected from each thyroid nodule and immediately stored in a proprietary nucleic acid preservative solution. The test is offered through a Clinical Laboratory Improvement Amendments of 1988 (CLIA)–certified reference laboratory (Veracyte) and generates 2 possible results, benign and suspicious.

ThyroSeq®

ThyroSeq v3 is based on next-generation sequencing of DNA and RNA. It has been expanded from prior versions to analyze 112 genes, providing information on >12,000 mutation hotspots and >150 gene fusion types. The test detects 4 classes of genetic alterations: (i) mutations (SNVs, indels); (ii) gene fusions; (iii) gene expression alterations; and (iv) copy number variations (CNVs). The test utilizes a proprietary Genomic Classifier (GC) based on the algorithmic analysis of all detected genetic alterations and is reported as either Positive or Negative. 1–2 drops from first FNA pass or 1 dedicated pass collected into nucleic acid preservative is used for testing. Cell blocks and FFPE tissue can also be used.

ThyGenX/ThyraMIR

ThyGenX uses a next-generation sequencing (NGS) platform to identify more than 100 genetic alterations across 8 genes associated with thyroid malignancy. It includes the original genetic alterations analyzed in the miRInform test and includes testing for the PIK3CA mutation, which is involved in the formation and progression of follicular carcinoma and anaplastic carcinoma. The test is offered in conjunction with ThyraMIR, when ThyGenX results are negative. ThyraMIR test is based on the analysis of 10 different microRNAs (miRNAs) including miR-29b-1-5p, miR-31-5p, miR-138-1-3p, miR-139-5p, miR-146b-5p, miR-155, miR-204-5p, miR-222-3p, miR-375, and miR-551b-3p. ThyGenX/ThyraMIR test requires only 1 dedicated FNA pass (at least 50 ng of cellular material must be collected into the provided RNA preservative vial RNARetain), and only cases diagnosed as AUS/FLUS or FN/SFN are accepted for ThyGenX analysis.

RosettaGX Reveal

RosettaGX Reveal testing involves expression analysis of 24 miRNAs by qRT-PCR. RosettaGX Reveal can be performed using the existing FNA smears from routinely prepared cytology slides from the patient’s initial biopsy. This test has not been available on the market since acquisition of Rosetta Genomics by Genoptix, Inc in 2018.

  • Preoperative Identification of Benign Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytopathology

Reported results are similar and usually reported as “Positive and followed with diagnosis such as:

  • Positive for medullary with probability High (>95%).Results would be followed with findings and interpretation such as: Strong overexpression of the Calcitonin and Chromogranin A genes was found in this sample. This, in addition to overexpression of the RET gene and very low expression of genes characteristic of thyroid follicular cells, is highly consistent with medullary thyroid carcinoma. No RET or RAS mutations were identified, which can be seen in ~20% of sporadic medullary carcinomas.
  • Another example is when BRAF is positive. Positive for Thyroid cancerBRAF V600E mutation was identified in this sample without other high-risk mutations. BRAF V600E is associated with a very high (~99%) probability of papillary thyroid carcinoma or related cancers.
  • Positive for parathyroid cancerStrong overexpression of the Parathyroid Hormone (PTH) and Chromogranin A (CHGA) genes and low expression of thyroid cell-related genes was found, which strongly suggests that the sampled nodule is composed of parathyroid cells.
  • Positive for NRAS mutationRAS mutation was identified in this sample together with copy number alterations and abnormal gene expression profile. Co-occurrence of these molecular alterations is associated with ~80% risk of cancer, typically follicular variant of papillary carcinoma. The remaining tumors are expected to be pre-malignant NIFTP or benign follicular adenomas. Risk of cancer recurrence associated with the combination of these alterations is expected to be low to intermediate.

Negative (Probability of Cancer or NIFTP: low)

Target Next Generation Sequencing from FNA, Gene Expression Microarray from FNA.

Fine needle aspiration (FNA), FNA rinsed in liquid cytology (ThinPrep), biopsy.

Thyroid biopsy, Solid tumor cancer panel by NGS, Thyroid panel, Thyroglobulin, serum, Thyroglobulin from FNA.
7-14 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Thyroid. 2016; 26(1):1–133. [PMID: 26462967]
  • Adv Anat Pathol. 2019 Mar;26(2):114-123. [PMID: 30664001]
  • Arch Pathol Lab Med. 2018 Apr;142(4):446-457. [PMID: 29336606]
  • Endocr Relat Cancer. 2018 Mar;25(3):R163-R177. [PMID: 29255094]
  • Arch Pathol Lab Med. 2016 Dec;140(12):1338-1344. [PMID: 27557410]
  • J Cancer Epidemiol. 2013;2013:965212. [PMID: 23737785]
  • Thyroid. 2016 Jan 1; 26(1): 1–133.[ PMC4739132]
  • Clin Endocrinol Metab. 2015;100(11):E1477–E1483. [PMID: 26353010]
  • PLoS Curr. 2013 Feb 11; 5. [PMC3574863]
  • Curr Opin Oncol. 2018 Jan;30(1):8-15. [PMID: 29028645]